E8
E8TN.F Eurobio Scientific Société anonyme
- Market cap
- EUR 261M
- P/E
- 37.0x
- P/B
- 1.36x
- ROE
- 2.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is E8TN.F undervalued?
Graham numberE8TN.F trades 49.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eurobio Scientific Société anonyme fundamental analysis
No fundamental analysis for Eurobio Scientific Société anonyme yet.
Eurobio Scientific Société anonyme stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eurobio Scientific Société anonyme
Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts; AlloMap, for heart transplant follow up; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies; TQS (Tetanus Quick Stick), a rapid…
Full company profileEurobio Scientific Société anonyme financial statements
Eurobio Scientific Société anonyme annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 28.4M | 43.1M | 51.1M | 59.5M | 189M | 185M | 153M | 130M | 155M | 169M |
| Gross Profit | 8.58M | 15.4M | 19.0M | 20.0M | 111M | 103M | 70.9M | 56.8M | 71.6M | 76.8M |
| Operating Income | -7.39M | -5.79M | -1.16M | 569K | 81.2M | 70.1M | 30.9M | 10.1M | 9.79M | 10.7M |
| EBITDA | - | -1.76M | 4.42M | 7.44M | 88.8M | 78.7M | 40.2M | 25.6M | 27.5M | 26.7M |
| Net Income | -7.73M | -9.97M | -2.77M | 3.15M | 73.5M | 60.5M | 24.9M | 4.84M | 4.00M | 4.87M |
| EPS | - | -1.03 | -0.28 | 0.28 | 6.48 | 5.34 | 2.44 | 0.48 | 0.40 | 0.48 |
| Balance Sheet | ||||||||||
| Total Assets | 31.9M | 71.6M | 69.9M | 81.0M | 172M | 210M | 331M | 316M | 257M | 257M |
| Total Liabilities | 19.7M | 39.9M | 40.3M | 44.4M | 64.5M | 49.0M | 158M | 141M | 78.3M | 72.8M |
| Shareholders' Equity | 12.2M | 31.7M | 29.6M | 36.6M | 108M | 161M | 173M | 175M | 179M | 184M |
| Cash & Short-term Investments | 7.91M | 11.8M | 11.0M | 7.62M | 65.1M | 92.9M | 47.5M | 49.3M | 21.8M | 20.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.32M | 2.48M | -523K | 4.99M | 54.9M | 65.9M | 43.1M | 26.8M | 16.7M | 18.9M |
| Capital Expenditure | 200K | 3.91M | 1.63M | 1.59M | 2.30M | 1.85M | 2.83M | 4.05M | 3.26M | 12.6M |
| Free Cash Flow | - | -1.44M | -2.15M | 3.40M | 52.6M | 64.1M | 40.2M | 22.7M | 13.4M | 6.28M |
| Ratios | ||||||||||
| ROE | -63.3% | -31.5% | -9.3% | 8.6% | 68.1% | 37.6% | 14.4% | 2.8% | 2.2% | 2.6% |
| ROA | -24.3% | -13.9% | -4.0% | 3.9% | 42.6% | 28.8% | 7.5% | 1.5% | 1.6% | 1.9% |
| Net Profit Margin | -27.2% | -23.1% | -5.4% | 5.3% | 38.8% | 32.7% | 16.3% | 3.7% | 2.6% | 2.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Eurobio Scientific Société anonyme dividends
Eurobio Scientific Société anonyme has not paid dividends in the last 10 fiscal years.
Who owns Eurobio Scientific Société anonyme
- Insiders 0.00%
- Institutions 91.12%
- Public & others 8.88%
- Shares outstanding 10.1M
- Free float 844K
Eurobio Scientific Société anonyme company profile
- Company name
- Eurobio Scientific Société anonyme
- Ticker
- E8TN.F
- ISIN
- FR0013240934
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 443
- Fiscal year end
- December
- Address
- 7 avenue de Scandinavie, Les Ulis, France, 91953
- Phone
- 33 1 69 79 64 80
- Website
- eurobio-scientific.com
About Eurobio Scientific Société anonyme
Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts; AlloMap, for heart transplant follow up; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies; TQS (Tetanus Quick Stick), a rapid test used in emergency departments or pharmacies to assess the vaccination status or immune protection of patients against tetanus; EBX molecular biology ranges in the field of infectious diseases; and EndoPredict range, a second-generation multigene expression test for postmenopausal women with early-stage breast cancer, ER positive, and HER2 negative, as well as Prolaris. It also provides GenDx, EurobioPlex, FungiLine, Biosafety PKA, and immunology products. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
Eurobio Scientific Société anonyme management
8- Mr. Denis FortierCEO & Chairman · born 1968
- Mr. Olivier BoscDeputy CEO & CFO · born 1974
- Ms. Cathie MarsaisDeputy CEO, COO, Operations, Affairs Quality & Regulatory · born 1982
- Mr. Jean-Michel Carle GrandmouginDeputy GM, Business Developer & Director · born 1961
- Mr. Maarten Penning Ph.D.CTO and Director of R&D
- Ms. Hanneke Merkens Ph.D.CMO, COM and Manager of International Product, Infectious & Transplant
- Mr. Thomas MoreauxCHRO & Ressources Humaines
- Mr. Thomas IffChief Business Officer